AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value

$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

KPIs

Operating metrics that drive AbbVie's business · fiscal year ends Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Metric	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30

Total Net Revenues — Worldwide ($M)($M)4	16,990	15,002	16,618	15,776	15,423	13,343	15,102	14,460	14,462	12,310	14,301	13,927
Total Net Revenues — United States ($M)($M)1	12,861	10,969	12,794	12,068	11,762	9,979	11,734	11,148	11,106	9,041	11,110	10,852
United States — Reported revenue growth YoY (%)(%)	9.3%	9.9%	9.0%	8.2%	5.9%	10.4%	5.6%	2.7%	3.6%	-1.7%	-8.9%	-7.7%
Total Net Revenues — International ($M)($M)2	4,129	4,033	3,824	3,708	3,661	3,364	3,368	3,312	3,356	3,269	3,191	3,075
International — Reported revenue growth YoY (%)(%)	12.8%	19.9%	13.5%	12.0%	9.1%	2.9%	5.6%	7.7%	6.8%	8.1%	8.9%	0.8%
International — Operational (constant-currency) revenue growth YoY (%)(%)	10.2%	11.4%	11.0%	9.0%	8.4%	8.3%	7.8%	12.4%	12.7%	11.6%	9.0%	1.4%
Worldwide — Reported revenue growth YoY (%)(%)	10.2%	12.4%	10.0%	9.1%	6.6%	8.4%	5.6%	3.8%	4.3%	0.7%	-5.4%	-6.0%
Worldwide — Operational (constant-currency) revenue growth YoY (%)(%)	9.5%	10.3%	9.5%	8.4%	6.5%	9.8%	6.1%	4.9%	5.6%	1.6%	-5.4%	-5.8%

Immunology Portfolio — Worldwide net revenues ($M)($M)7	8,786	7,290	8,626	7,885	7,631	6,264	7,294	7,046	6,971	5,371	6,953	6,783
Immunology Portfolio — U.S. net revenues ($M)($M)1	6,957	5,537	6,961	6,263	6,097	4,883	5,905	5,713	5,717	4,152	5,774	5,696
Immunology Portfolio — U.S. reported growth YoY (%)(%)	14.1%	13.4%	17.9%	9.6%	6.7%	17.6%	2.2%	0.3%	-0.2%	-8.5%	-17.2%	-14.7%
Immunology Portfolio — International net revenues ($M)($M)2	1,829	1,753	1,665	1,622	1,534	1,381	1,389	1,333	1,254	1,219	1,179	1,087
Immunology Portfolio — International reported growth YoY (%)(%)	19.2%	26.9%	19.7%	21.7%	22.3%	13.4%	17.8%	22.7%	15.9%	16.0%	24.3%	12.1%
Immunology Portfolio — International operational (constant-currency) growth YoY (%)(%)	16.8%	17.3%	16.8%	17.9%	20.7%	20.1%	20.2%	28.4%	23.5%	20.5%	24.0%	11.9%
Immunology Portfolio — Worldwide reported growth YoY (%)(%)	15.1%	16.4%	18.3%	11.9%	9.5%	16.6%	4.9%	3.9%	2.3%	-3.9%	-12.3%	-11.3%
Immunology Portfolio — Worldwide operational (constant-currency) growth YoY (%)(%)	14.6%	14.3%	17.7%	11.2%	9.2%	18.1%	5.3%	4.8%	3.5%	-3.1%	-12.3%	-11.3%
Skyrizi (risankizumab) — Worldwide net revenues ($M)($M)4	5,505	4,483	5,006	4,708	4,423	3,425	3,778	3,205	2,727	2,008	2,394	2,126
Skyrizi (risankizumab) — U.S. net revenues ($M)($M)1	4,767	3,775	4,355	4,085	3,843	2,919	3,312	2,778	2,340	1,656	2,105	1,875
Skyrizi (risankizumab) — U.S. reported growth YoY (%)(%)	24.0%	29.3%	31.5%	47.0%	64.3%	76.2%	57.3%	48.3%	43.2%	45.3%	50.0%	53.5%
Skyrizi (risankizumab) — International net revenues ($M)($M)2	738	708	651	623	580	506	466	427	387	352	289	251
Skyrizi (risankizumab) — International reported growth YoY (%)(%)	27.3%	39.8%	39.8%	45.9%	49.7%	43.9%	61.1%	70.0%	55.5%	59.4%	67.5%	42.5%
Skyrizi (risankizumab) — International operational (constant-currency) growth YoY (%)(%)	24.2%	28.0%	35.1%	40.2%	47.2%	52.3%	62.4%	75.7%	61.8%	61.6%	64.4%	40.7%
Skyrizi (risankizumab) — Worldwide reported growth YoY (%)(%)	24.4%	30.9%	32.5%	46.8%	62.2%	70.5%	57.7%	50.8%	44.8%	47.6%	51.9%	52.1%
Skyrizi (risankizumab) — Worldwide operational (constant-currency) growth YoY (%)(%)	24.0%	29.2%	31.9%	46.0%	61.8%	72.0%	57.9%	51.5%	45.6%	48.0%	51.6%	51.9%
Rinvoq (upadacitinib) — Worldwide net revenues ($M)($M)4	2,525	2,119	2,374	2,184	2,028	1,718	1,834	1,614	1,430	1,093	1,255	1,110
Rinvoq (upadacitinib) — U.S. net revenues ($M)($M)1	1,765	1,405	1,709	1,559	1,452	1,220	1,347	1,170	1,017	725	929	801
Rinvoq (upadacitinib) — U.S. reported growth YoY (%)(%)	21.6%	15.1%	26.9%	33.3%	42.7%	68.3%	45.0%	45.9%	57.9%	61.4%	63.9%	59.0%
Rinvoq (upadacitinib) — International net revenues ($M)($M)2	760	714	665	625	576	498	487	444	413	368	326	309
Rinvoq (upadacitinib) — International reported growth YoY (%)(%)	31.9%	43.4%	36.4%	40.7%	39.6%	35.3%	49.5%	44.0%	51.1%	55.3%	60.2%	61.8%
Rinvoq (upadacitinib) — International operational (constant-currency) growth YoY (%)(%)	29.2%	32.6%	33.2%	36.5%	37.5%	42.8%	53.1%	51.6%	62.6%	62.8%	59.8%	61.2%
Rinvoq (upadacitinib) — Worldwide reported growth YoY (%)(%)	24.5%	23.3%	29.5%	35.3%	41.8%	57.2%	46.2%	45.3%	55.8%	59.3%	62.9%	59.8%
Rinvoq (upadacitinib) — Worldwide operational (constant-currency) growth YoY (%)(%)	23.7%	20.2%	28.6%	34.1%	41.2%	59.7%	47.1%	47.4%	59.2%	61.9%	62.8%	59.6%
Humira (adalimumab) — Worldwide net revenues ($M)($M)4	756	688	1,246	993	1,180	1,121	1,682	2,227	2,814	2,270	3,304	3,547
Humira (adalimumab) — U.S. net revenues ($M)($M)1	425	357	897	619	802	744	1,246	1,765	2,360	1,771	2,740	3,020
Humira (adalimumab) — U.S. reported growth YoY (%)(%)	-47.0%	-52.0%	-27.9%	-65.0%	-66.0%	-58.0%	-54.5%	-41.6%	-31.6%	-39.9%	-45.3%	-39.1%
Humira (adalimumab) — International net revenues ($M)($M)2	331	331	349	374	378	377	436	462	454	499	564	527
Humira (adalimumab) — International reported growth YoY (%)(%)	-12.5%	-12.3%	-20.3%	-18.9%	-16.8%	-24.4%	-22.7%	-12.4%	-18.9%	-15.8%	-1.5%	-12.6%
Humira (adalimumab) — International operational (constant-currency) growth YoY (%)(%)	-13.2%	-17.4%	-21.0%	-20.5%	-17.2%	-19.5%	-20.5%	-7.8%	-12.5%	-11.6%	-1.0%	-12.2%
Humira (adalimumab) — Worldwide reported growth YoY (%)(%)	-35.9%	-38.6%	-25.9%	-55.4%	-58.1%	-50.6%	-49.1%	-37.2%	-29.8%	-35.9%	-40.8%	-36.2%
Humira (adalimumab) — Worldwide operational (constant-currency) growth YoY (%)(%)	-36.1%	-40.3%	-26.1%	-55.7%	-58.2%	-49.5%	-48.7%	-36.5%	-28.9%	-35.2%	-40.7%	-36.2%

Neuroscience Portfolio — Worldwide net revenues ($M)($M)11	3,228	2,875	2,961	2,841	2,683	2,282	2,509	2,363	2,162	1,965	2,094	2,043
Neuroscience Portfolio — U.S. net revenues ($M)($M)1	2,771	2,459	2,572	2,463	2,333	1,972	2,210	2,088	1,895	1,714	1,861	1,817
Neuroscience Portfolio — U.S. reported growth YoY (%)(%)	18.8%	24.7%	16.3%	18.0%	23.2%	15.0%	18.8%	14.9%	14.9%	17.1%	23.7%	24.0%
Neuroscience Portfolio — International net revenues ($M)($M)2	457	416	389	378	350	310	299	275	267	251	233	226
Neuroscience Portfolio — International reported growth YoY (%)(%)	29.9%	34.4%	30.3%	37.2%	30.6%	24.0%	28.4%	21.2%	13.5%	7.9%	14.7%	8.9%
Neuroscience Portfolio — International operational (constant-currency) growth YoY (%)(%)	25.7%	21.8%	25.6%	32.3%	28.7%	31.0%	29.3%	25.1%	17.3%	8.9%	13.0%	8.4%
Neuroscience Portfolio — Worldwide reported growth YoY (%)(%)	20.3%	26.0%	17.9%	20.2%	24.2%	16.1%	19.8%	15.6%	14.7%	15.9%	22.6%	22.1%
Neuroscience Portfolio — Worldwide operational (constant-currency) growth YoY (%)(%)	19.8%	24.3%	17.3%	19.6%	24.0%	17.0%	19.9%	16.0%	15.2%	16.0%	22.4%	22.0%
Vraylar (cariprazine) — Worldwide net revenues ($M)($M)4	1,071	905	1,022	934	900	765	924	875	774	694	789	751
Vraylar (cariprazine) — U.S. net revenues ($M)($M)1	1,068	902	1,020	931	898	763	922	873	773	692	788	750
Vraylar (cariprazine) — U.S. reported growth YoY (%)(%)	18.9%	18.2%	10.5%	6.7%	16.2%	10.3%	17.1%	16.5%	17.5%	23.5%	39.6%	35.2%
Vraylar (cariprazine) — International net revenues ($M)($M)2	3	3	2	3	2	2	2	2	1	2	1	1
Vraylar (cariprazine) — International reported growth YoY (%)(%)	30.1%	67.6%	21.7%	31.5%	72.8%	13.1%	25.8%	49.3%	68.8%
Vraylar (cariprazine) — International operational (constant-currency) growth YoY (%)(%)	28.5%	58.9%	24.5%	32.3%	76.8%	20.2%	26.4%	51.9%	69.2%
Vraylar (cariprazine) — Worldwide reported growth YoY (%)(%)	18.9%	18.4%	10.5%	6.7%	16.3%	10.3%	17.1%	16.6%	17.6%	23.6%	39.8%	35.4%
Vraylar (cariprazine) — Worldwide operational (constant-currency) growth YoY (%)(%)	18.9%	18.4%	10.5%	6.7%	16.3%	10.3%	17.1%	16.6%	17.6%	23.6%	39.8%	35.4%
Botox Therapeutic (onabotulinumtoxinA) — Worldwide net revenues ($M)($M)4	1,042	1,009	990	985	928	866	873	848	814	748	776	748
Botox Therapeutic (onabotulinumtoxinA) — U.S. net revenues ($M)($M)1	864	842	828	825	775	723	730	708	669	611	649	626
Botox Therapeutic (onabotulinumtoxinA) — U.S. reported growth YoY (%)(%)	11.4%	16.5%	13.5%	16.6%	15.9%	18.2%	12.4%	13.1%	8.9%	4.1%	5.7%	7.2%
Botox Therapeutic (onabotulinumtoxinA) — International net revenues ($M)($M)2	178	167	162	160	153	143	143	140	145	137	127	122
Botox Therapeutic (onabotulinumtoxinA) — International reported growth YoY (%)(%)	16.2%	16.3%	13.1%	13.4%	5.7%	4.8%	13.2%	14.6%	7.9%	3.9%	11.5%	6.5%
Botox Therapeutic (onabotulinumtoxinA) — International operational (constant-currency) growth YoY (%)(%)	12.5%	6.7%	10.7%	11.3%	6.0%	11.4%	16.3%	20.7%	13.0%	6.3%	11.9%	8.6%
Botox Therapeutic (onabotulinumtoxinA) — Worldwide reported growth YoY (%)(%)	12.2%	16.5%	13.4%	16.1%	14.1%	15.8%	12.5%	13.4%	8.7%	4.1%	6.6%	7.1%
Botox Therapeutic (onabotulinumtoxinA) — Worldwide operational (constant-currency) growth YoY (%)(%)	11.6%	14.9%	13.0%	15.8%	14.2%	17.0%	13.0%	14.4%	9.6%	4.5%	6.7%	7.4%
Ubrelvy (ubrogepant) — Worldwide net revenues ($M)($M)4	392	339	339	354	338	240	303	269	231	203	234	233
Ubrelvy (ubrogepant) — U.S. net revenues ($M)($M)1	379	330	332	344	330	233	296	261	227	197	229	230
Ubrelvy (ubrogepant) — U.S. reported growth YoY (%)(%)	15.0%	41.7%	12.3%	31.4%	46.5%	17.6%	28.9%	13.6%	16.6%	31.5%	16.9%	43.7%
Ubrelvy (ubrogepant) — International net revenues ($M)($M)2	13	9	7	10	8	7	7	8	4	6	5	3
Ubrelvy (ubrogepant) — International reported growth YoY (%)(%)	54.9%	29.2%	-3.7%	34.1%	73.9%	23.3%	65.3%		81.6%
Ubrelvy (ubrogepant) — International operational (constant-currency) growth YoY (%)(%)	52.5%	22.9%	-3.0%	34.2%	76.7%	29.3%	66.2%		82.3%
Ubrelvy (ubrogepant) — Worldwide reported growth YoY (%)(%)	16.0%	41.4%	12.0%	31.5%	47.1%	17.8%	29.6%	15.3%	17.5%	33.8%	18.9%	45.6%
Ubrelvy (ubrogepant) — Worldwide operational (constant-currency) growth YoY (%)(%)	15.9%	41.2%	12.0%	31.5%	47.2%	18.0%	29.6%	15.3%	17.5%	33.8%	18.9%	45.6%
Qulipta (atogepant) — Worldwide net revenues ($M)($M)4	350	296	288	288	267	193	201	176	150	131	114	132
Qulipta (atogepant) — U.S. net revenues ($M)($M)1	289	250	245	252	237	172	186	168	146	128	113	131
Qulipta (atogepant) — U.S. reported growth YoY (%)(%)	22.1%	45.4%	30.9%	50.2%	62.8%	34.2%	65.7%	28.3%	52.8%	94.5%
Qulipta (atogepant) — International net revenues ($M)($M)	61	46	43	36	30	21	15	8	4	3	1	1
Qulipta (atogepant) — Worldwide reported growth YoY (%)(%)	30.9%	53.6%	42.6%	64.1%	77.5%	47.6%	76.4%	33.6%	56.3%	97.7%
Qulipta (atogepant) — Worldwide operational (constant-currency) growth YoY (%)(%)	30.3%	51.3%	41.8%	63.1%	76.9%	48.3%	76.2%	33.6%	56.3%	97.7%
Vyalev (foscarbidopa/foslevodopa) — Worldwide net revenues ($M)($M)2	256	201	183	138	98	63	44	28	18	9
Vyalev (foscarbidopa/foslevodopa) — U.S. net revenues ($M)($M)	128	89	86	53	22	6	1	0	0	0
Vyalev (foscarbidopa/foslevodopa) — International net revenues ($M)($M)	128	112	97	85	76	57	43	28	18	9
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — Worldwide net revenues ($M)($M)4			92	96	97	96	108	111	113	115	115	118
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — U.S. net revenues ($M)($M)1			17	16	20	20	24	24	23	25	23	25
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — U.S. reported growth YoY (%)(%)			-31.6%	-29.9%	-13.6%	-19.4%	2.8%	-4.7%	-2.6%	-2.6%	3.8%	10.6%
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — International net revenues ($M)($M)2			75	80	77	76	84	87	90	90	92	93
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — International reported growth YoY (%)(%)			-10.4%	-9.0%	-13.7%	-16.0%	-8.1%	-7.1%	-3.2%	-2.7%	9.0%	6.6%
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — International operational (constant-currency) growth YoY (%)(%)			-14.9%	-13.8%	-16.3%	-11.7%	-9.7%	-6.4%	-1.7%	-3.7%	4.2%	2.3%
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — Worldwide reported growth YoY (%)(%)			-15.1%	-13.5%	-13.7%	-16.7%	-5.8%	-6.6%	-3.1%	-2.7%	7.9%	7.4%
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — Worldwide operational (constant-currency) growth YoY (%)(%)			-18.6%	-17.3%	-15.7%	-13.3%	-7.0%	-6.0%	-1.9%	-3.5%	4.1%	4.0%
Other Neuroscience — Worldwide net revenues ($M)($M)4	117	125	47	46	152	155	56	56	62	65	63	61
Other Neuroscience — U.S. net revenues ($M)($M)1	43	46	44	42	71	75	51	54	57	61	59	55
Other Neuroscience — U.S. reported growth YoY (%)(%)	-38.6%	-38.9%	-13.9%	-21.7%	-11.4%	-9.5%	-11.7%	-4.1%	-10.1%	-18.5%	4.2%	-31.9%
Other Neuroscience — International net revenues ($M)($M)2	74	79	3	4	81	80	5	2	5	4	4	6
Other Neuroscience — International reported growth YoY (%)(%)	-8.9%	-1.5%	-20.1%	92.3%	-23.3%	-1.0%					61.7%	6.2%
Other Neuroscience — International operational (constant-currency) growth YoY (%)(%)	-12.4%	-11.7%	-19.0%	94.0%	-21.3%	6.5%					62.5%	9.6%
Other Neuroscience — Worldwide reported growth YoY (%)(%)	-22.7%	-19.6%	-14.4%	-17.3%	-12.3%	-8.9%	50.9%	36.4%	16.6%	-6.9%	8.5%	-29.9%
Other Neuroscience — Worldwide operational (constant-currency) growth YoY (%)(%)	-24.6%	-24.8%	-14.3%	-17.2%	-12.2%	-8.4%	50.4%	37.1%	17.5%	-6.7%	8.6%	-29.7%

Oncology Portfolio — Worldwide net revenues ($M)($M)9	1,650	1,631	1,664	1,682	1,676	1,633	1,691	1,687	1,634	1,543	1,509	1,512
Oncology Portfolio — U.S. net revenues ($M)($M)1	936	882	997	1,030	1,026	1,027	1,102	1,113	1,037	967	971	973
Oncology Portfolio — U.S. reported growth YoY (%)(%)	-8.7%	-14.1%	-9.6%	-7.4%	-1.0%	6.0%	13.4%	14.4%	11.3%	7.3%	-12.3%	-12.3%
Oncology Portfolio — International net revenues ($M)($M)2	714	749	667	652	650	606	589	574	597	576	538	539
Oncology Portfolio — International reported growth YoY (%)(%)	9.9%	23.4%	13.6%	13.4%	8.7%	5.4%	9.4%	6.5%	9.3%	12.1%	2.9%	-0.4%
Oncology Portfolio — International operational (constant-currency) growth YoY (%)(%)	7.6%	15.7%	10.8%	10.4%	8.3%	10.0%	11.8%	10.3%	13.8%	14.3%	2.3%	-1.0%
Oncology Portfolio — Worldwide reported growth YoY (%)(%)	-1.5%	-0.2%	-1.5%	-0.3%	2.6%	5.8%	12.0%	11.6%	10.5%	9.0%	-7.4%	-8.4%
Oncology Portfolio — Worldwide operational (constant-currency) growth YoY (%)(%)	-2.4%	-3.0%	-2.5%	-1.3%	2.4%	7.5%	12.9%	13.0%	12.2%	9.8%	-7.6%	-8.6%
Venclexta (venetoclax) — Worldwide net revenues ($M)($M)4	771	770	710	726	691	665	655	677	637	614	589	590
Venclexta (venetoclax) — U.S. net revenues ($M)($M)1	369	341	332	341	321	312	313	340	300	281	276	281
Venclexta (venetoclax) — U.S. reported growth YoY (%)(%)	14.8%	9.2%	6.2%		7.4%	11.0%	13.0%	21.5%	12.8%	6.2%	3.1%	8.1%
Venclexta (venetoclax) — International net revenues ($M)($M)2	402	429	378	385	370	353	342	337	337	333	313	309
Venclexta (venetoclax) — International reported growth YoY (%)(%)	8.8%	21.4%	10.8%	14.3%	9.5%	6.0%	9.3%	8.9%	10.4%	21.9%	26.4%	21.1%
Venclexta (venetoclax) — International operational (constant-currency) growth YoY (%)(%)	5.0%	10.1%	6.6%	10.0%	9.1%	13.4%	13.2%	15.4%	18.4%	26.1%	25.1%	19.9%
Venclexta (venetoclax) — Worldwide reported growth YoY (%)(%)	11.6%	15.7%	8.6%	7.1%	8.5%	8.3%	11.0%	14.8%	11.5%	14.2%	14.3%	14.6%
Venclexta (venetoclax) — Worldwide operational (constant-currency) growth YoY (%)(%)	9.6%	9.7%	6.4%	4.9%	8.3%	12.3%	13.0%	18.2%	15.8%	16.3%	13.7%	14.0%
Imbruvica (ibrutinib) — Worldwide net revenues ($M)($M)4	532	556	671	706	754	738	848	828	833	838	903	908
Imbruvica (ibrutinib) — U.S. net revenues ($M)($M)1	337	332	469	507	543	529	625	618	595	610	683	678
Imbruvica (ibrutinib) — U.S. reported growth YoY (%)(%)	-37.8%	-37.4%	-25.0%	-17.9%	-8.9%	-13.3%	-8.6%	-8.9%	-10.6%	-4.3%	-18.6%	-20.2%
Imbruvica (ibrutinib) — International net revenues ($M)($M)2	195	224	202	199	211	209	223	210	238	228	220	230
Imbruvica (ibrutinib) — International reported growth YoY (%)(%)	-7.8%	7.2%	-9.0%	-5.8%	-11.2%	-8.2%	1.2%	-8.4%	-1.4%	-5.1%	-20.0%	-19.6%
Imbruvica (ibrutinib) — International operational (constant-currency) growth YoY (%)(%)	-7.8%	7.2%	-9.0%	-5.8%	-11.2%	-8.2%	1.2%	-8.4%	-1.4%	-5.1%	-20.0%	-19.6%
Imbruvica (ibrutinib) — Worldwide reported growth YoY (%)(%)	-29.4%	-24.7%	-20.8%	-14.8%	-9.5%	-11.9%	-6.2%	-8.8%	-8.2%	-4.5%	-19.0%	-20.0%
Imbruvica (ibrutinib) — Worldwide operational (constant-currency) growth YoY (%)(%)	-29.4%	-24.7%	-20.8%	-14.8%	-9.5%	-11.9%	-6.2%	-8.8%	-8.2%	-4.5%	-19.0%	-20.0%
Elahere (mirvetuximab soravtansine) — Worldwide net revenues ($M)($M)4	211	198	182	170	159	179	148	139	128	64
Elahere (mirvetuximab soravtansine) — U.S. net revenues ($M)($M)1	161	160	154	150	138	165	146	139	128	64	0	0
Elahere (mirvetuximab soravtansine) — U.S. reported growth YoY (%)(%)	17.1%	-2.9%	5.0%	8.6%	8.0%
Elahere (mirvetuximab soravtansine) — International net revenues ($M)($M)	50	38	28	20	21	14	2	0	0	0
Elahere (mirvetuximab soravtansine) — Worldwide reported growth YoY (%)(%)	33.1%	10.7%	22.6%	23.3%	24.2%
Elahere (mirvetuximab soravtansine) — Worldwide operational (constant-currency) growth YoY (%)(%)	31.8%	8.3%	21.3%	22.4%	23.7%
Epkinly (epcoritamab) — Worldwide net revenues ($M)($M)2	103	83	81	69	70	51	40	43	36	27	17	14
Epkinly (epcoritamab) — U.S. net revenues ($M)($M)1	64	51	52	44	49	36	36	31	29	22	14	14
Epkinly (epcoritamab) — U.S. reported growth YoY (%)(%)	62.4%	22.1%	23.8%	30.8%	57.4%	66.7%	48.9%	13.4%
Epkinly (epcoritamab) — International net revenues ($M)($M)	39	32	29	25	21	15	4	12	7	5	3	0
Other Oncology — Worldwide net revenues ($M)($M)1	33	24	20	11	2	0	0	0	0
Other Oncology — U.S. net revenues ($M)($M)	33	24	20	11	2	0	0	0	0

Aesthetics Portfolio — Worldwide net revenues ($M)($M)7	1,282	1,186	1,286	1,193	1,279	1,102	1,298	1,239	1,390	1,249	1,371	1,239
Aesthetics Portfolio — U.S. net revenues ($M)($M)1	761	704	811	742	797	640	839	791	863	776	884	759
Aesthetics Portfolio — U.S. reported growth YoY (%)(%)	-4.4%	9.8%	-3.3%	-6.2%	-7.8%	-17.4%	-5.0%	3.9%	4.4%	-0.3%	5.7%
Aesthetics Portfolio — International net revenues ($M)($M)2	521	482	475	451	482	462	459	448	527	473	487	480
Aesthetics Portfolio — International reported growth YoY (%)(%)	8.1%	4.5%	3.3%	0.8%	-8.5%	-2.4%	-5.6%	-6.4%	-5.4%	-9.4%	7.6%	-11.4%
Aesthetics Portfolio — International operational (constant-currency) growth YoY (%)(%)	5.0%	-1.5%	2.5%	-0.6%	-8.3%	1.6%	-3.2%	-1.6%	0.4%	-5.5%	9.0%	-9.7%
Aesthetics Portfolio — Worldwide reported growth YoY (%)(%)	0.3%	7.6%	-0.9%	-3.7%	-8.1%	-11.7%	-5.2%	-0.1%	0.5%	-4.0%	6.4%	-4.7%
Aesthetics Portfolio — Worldwide operational (constant-currency) growth YoY (%)(%)	-0.9%	5.1%	-1.2%	-4.2%	-8.0%	-10.2%	-4.4%	1.8%	2.8%	-2.5%	6.9%	-4.0%
Botox Cosmetic (onabotulinumtoxinA) — Worldwide net revenues ($M)($M)4	728	668	717	637	692	556	687	671	729	633	718	620
Botox Cosmetic (onabotulinumtoxinA) — U.S. net revenues ($M)($M)1	400	371	420	379	410	295	429	414	450	389	453	388
Botox Cosmetic (onabotulinumtoxinA) — U.S. reported growth YoY (%)(%)	-2.4%	25.8%	-2.1%	-8.4%	-8.7%	-24.3%	-5.2%	6.5%	7.1%	-4.9%	7.3%	5.0%
Botox Cosmetic (onabotulinumtoxinA) — International net revenues ($M)($M)2	328	297	297	258	282	261	258	257	279	244	265	232
Botox Cosmetic (onabotulinumtoxinA) — International reported growth YoY (%)(%)	16.4%	13.9%	14.7%	0.7%	0.9%	6.9%	-2.5%	10.9%	5.2%	-2.2%	20.6%	-13.3%
Botox Cosmetic (onabotulinumtoxinA) — International operational (constant-currency) growth YoY (%)(%)	12.1%	7.1%	13.5%	-0.6%	1.2%	11.1%	-0.3%	15.5%	10.9%	1.2%	22.0%	-10.9%
Botox Cosmetic (onabotulinumtoxinA) — Worldwide reported growth YoY (%)(%)	5.2%	20.2%	4.2%	-4.9%	-5.0%	-12.3%	-4.2%	8.2%	6.4%	-3.9%	11.8%	-2.7%
Botox Cosmetic (onabotulinumtoxinA) — Worldwide operational (constant-currency) growth YoY (%)(%)	3.4%	17.0%	3.8%	-5.4%	-4.9%	-10.7%	-3.4%	9.9%	8.6%	-2.6%	12.3%	-1.7%
Juvederm Collection — Worldwide net revenues ($M)($M)4	245	232	249	253	260	231	279	258	343	297	334	321
Juvederm Collection — U.S. net revenues ($M)($M)1	103	85	107	98	105	75	120	105	138	106	156	116
Juvederm Collection — U.S. reported growth YoY (%)(%)	-2.0%	12.2%	-11.0%	-7.5%	-23.6%	-29.0%	-22.5%	-10.2%	10.4%	-13.2%	20.5%	-6.4%
Juvederm Collection — International net revenues ($M)($M)2	142	147	142	155	155	156	159	153	205	191	178	205
Juvederm Collection — International reported growth YoY (%)(%)	-8.6%	-5.3%	-10.5%	1.4%	-24.4%	-18.5%	-10.9%	-25.1%	-15.6%	-18.1%	-8.0%	-9.8%
Juvederm Collection — International operational (constant-currency) growth YoY (%)(%)	-9.7%	-10.3%	-10.7%	-0.2%	-24.4%	-15.0%	-8.7%	-20.8%	-10.0%	-14.0%	-7.3%	-8.7%
Juvederm Collection — Worldwide reported growth YoY (%)(%)	-6.0%	0.4%	-10.7%	-2.2%	-24.0%	-22.2%	-16.3%	-19.7%	-6.8%	-16.4%	3.4%	-8.6%
Juvederm Collection — Worldwide operational (constant-currency) growth YoY (%)(%)	-6.6%	-2.9%	-10.8%	-3.2%	-24.0%	-20.0%	-15.1%	-16.9%	-3.1%	-13.7%	3.8%	-7.9%
Other Aesthetics — Worldwide net revenues ($M)($M)4	309	286	320	303	327	315	332	310	318	319	319	298
Other Aesthetics — U.S. net revenues ($M)($M)1	258	248	284	265	282	270	290	272	275	281	275	255
Other Aesthetics — U.S. reported growth YoY (%)(%)	-8.3%	-8.4%	-1.8%	-2.3%	1.6%	-3.5%	5.2%	6.4%	-2.3%	13.7%	-3.3%	-4.0%
Other Aesthetics — International net revenues ($M)($M)2	51	38	36	38	45	45	42	38	43	38	44	43
Other Aesthetics — International reported growth YoY (%)(%)	14.1%	-15.7%	-14.5%	-0.8%	5.8%	18.1%	-2.3%	-10.0%	-11.7%	-3.7%	12.6%	-8.1%
Other Aesthetics — International operational (constant-currency) growth YoY (%)(%)	11.8%	-20.5%	-15.0%	-2.2%	6.4%	23.2%	1.5%	-2.0%	-4.1%	1.2%	16.9%	-7.0%
Other Aesthetics — Worldwide reported growth YoY (%)(%)	-5.2%	-9.4%	-3.4%	-2.1%	2.2%	-0.9%	4.2%	4.0%	-3.6%	11.3%	-1.5%	-4.6%
Other Aesthetics — Worldwide operational (constant-currency) growth YoY (%)(%)	-5.5%	-10.1%	-3.5%	-2.3%	2.3%	-0.3%	4.7%	5.1%	-2.5%	12.0%	-1.0%	-4.4%
Other Key Products Portfolio — Worldwide net revenues ($M)($M)8	935	995	884	1,006	1,037	809	912	874	962	900	968	963
Other Key Products Portfolio — U.S. net revenues ($M)($M)1	761	816	711	829	835	636	748	710	750	686	778	751
Other Key Products Portfolio — U.S. reported growth YoY (%)(%)	-9.1%	28.5%	-5.1%	16.9%	11.2%	-7.2%	-3.8%	-5.6%	0.9%	-5.6%	-1.5%	-4.6%
Other Key Products Portfolio — International net revenues ($M)($M)2	174	179	173	177	202	173	164	164	212	214	190	212
Other Key Products Portfolio — International reported growth YoY (%)(%)	-13.4%	3.0%	5.3%	8.1%	-4.4%	-19.4%	-14.1%	-22.1%	4.1%	6.3%	-2.3%	4.4%
Other Key Products Portfolio — International operational (constant-currency) growth YoY (%)(%)	-15.5%	-7.9%	1.3%	3.4%	-5.8%	-14.8%	-13.9%	-19.5%	8.8%	8.8%	-1.0%	4.9%
Other Key Products Portfolio — Worldwide reported growth YoY (%)(%)	-9.9%	23.0%	-3.2%	15.2%	7.8%	-10.1%	-5.8%	-9.3%	1.6%	-3.0%	-1.7%	-2.8%
Other Key Products Portfolio — Worldwide operational (constant-currency) growth YoY (%)(%)	-10.3%	20.7%	-3.9%	14.3%	7.5%	-9.0%	-5.8%	-8.7%	2.6%	-2.4%	-1.4%	-2.7%
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — Worldwide net revenues ($M)($M)4	295	351	324	312	375	306	291	302	369	349	309	370
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — U.S. net revenues ($M)($M)1	133	183	163	146	184	142	137	147	167	144	128	167
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — U.S. reported growth YoY (%)(%)	-27.7%	28.3%	17.9%	-0.2%	9.7%	-0.7%	7.8%	-12.7%	-13.2%	-15.8%	-33.5%	-12.3%
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — International net revenues ($M)($M)2	162	168	161	166	191	164	154	155	202	205	181	203
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — International reported growth YoY (%)(%)	-14.9%	2.4%	4.9%	6.9%	-5.1%	-20.4%	-15.4%	-23.1%	3.8%	6.2%	-3.0%	5.2%
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — International operational (constant-currency) growth YoY (%)(%)	-16.9%	-8.6%	0.8%	2.1%	-6.5%	-15.8%	-15.1%	-20.5%	8.8%	9.0%	-1.5%	5.8%
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — Worldwide reported growth YoY (%)(%)	-21.2%	14.5%	11.0%	3.5%	1.6%	-12.3%	-5.8%	-18.4%	-4.7%	-4.1%	-18.5%	-3.5%
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — Worldwide operational (constant-currency) growth YoY (%)(%)	-22.2%	8.6%	8.9%	1.0%	0.8%	-9.6%	-5.6%	-17.0%	-2.2%	-2.6%	-17.8%	-3.2%
Creon (pancrelipase) — Worldwide net revenues ($M)($M)3	345	361	385	368	404	355	388	338	372	285	376	305
Creon (pancrelipase) — U.S. net revenues ($M)($M)1	345	361	385	368	404	355	388	338	372	285	376	305
Creon (pancrelipase) — U.S. reported growth YoY (%)(%)	-14.7%	1.8%	-0.8%	9.1%	8.4%	24.6%	3.3%	10.6%	32.1%	-6.6%	11.5%	-9.1%
Creon (pancrelipase) — Worldwide reported growth YoY (%)(%)	-14.7%	1.8%	-0.8%	9.1%	8.4%	24.6%	3.3%	10.6%	32.1%	-6.6%	11.5%	-9.1%
Creon (pancrelipase) — Worldwide operational (constant-currency) growth YoY (%)(%)	-14.7%	1.8%	-0.8%	9.1%	8.4%	24.6%	3.3%	10.6%	32.1%	-6.6%	11.5%	-9.1%
Linzess/Constella (linaclotide) — Worldwide net revenues ($M)($M)2	295	283	175	326	258	148	233	234	221	266	283	288
Linzess/Constella (linaclotide) — U.S. net revenues ($M)($M)	283	272	163	315	247	139	223	225	211	257	274	279
Linzess/Constella (linaclotide) — International net revenues ($M)($M)	12	11	12	11	11	9	10	9	10	9	9	9
All Other Products — Worldwide net revenues ($M)($M)	1,109	1,025	617	660	1,117	1,253	752	726	810	744	821	782
Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide net revenues ($M)($M)9			580	509	514	506	646	525	533	538	585	605
Eye Care Portfolio [folded into All Other in Q1 2026] — U.S. net revenues ($M)($M)1			286	221	226	221	358	240	239	227	314	310
Eye Care Portfolio [folded into All Other in Q1 2026] — U.S. reported growth YoY (%)(%)			-19.7%	-8.0%	-5.7%	-2.6%	12.8%	-22.9%	-21.8%	-29.2%	-6.9%	-14.0%
Eye Care Portfolio [folded into All Other in Q1 2026] — International net revenues ($M)($M)2			294	288	288	285	288	285	294	311	271	295
Eye Care Portfolio [folded into All Other in Q1 2026] — International reported growth YoY (%)(%)			1.6%	1.3%	-2.4%	-8.0%	7.3%	-3.5%	-4.7%	7.6%	7.2%	13.1%
Eye Care Portfolio [folded into All Other in Q1 2026] — International operational (constant-currency) growth YoY (%)(%)			-0.4%	-1.0%	-1.5%	-2.0%	9.8%	1.2%	0.2%	10.3%	6.7%	13.9%
Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide reported growth YoY (%)(%)			-10.1%	-3.0%	-3.9%	-5.7%	10.2%	-13.5%	-13.3%	-11.7%	-0.9%	-2.7%
Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide operational (constant-currency) growth YoY (%)(%)			-11.0%	-4.2%	-3.4%	-2.2%	11.4%	-11.2%	-10.9%	-10.4%	-1.1%	-2.4%
Ozurdex (dexamethasone intravitreal implant) — Worldwide net revenues ($M)($M)4			128	117	125	123	120	119	124	131	118	120
Ozurdex (dexamethasone intravitreal implant) — U.S. net revenues ($M)($M)1			32	32	30	30	36	33	35	34	36	34
Ozurdex (dexamethasone intravitreal implant) — U.S. reported growth YoY (%)(%)			-10.4%	-4.9%	-12.6%	-12.1%	-3.2%	-2.3%	4.2%	-13.7%	3.0%	-4.5%
Ozurdex (dexamethasone intravitreal implant) — International net revenues ($M)($M)2			96	85	95	93	84	86	89	97	82	86
Ozurdex (dexamethasone intravitreal implant) — International reported growth YoY (%)(%)			14.1%	-0.3%	5.8%	-3.8%	3.0%	-0.3%	4.6%	27.9%	17.0%	22.3%
Ozurdex (dexamethasone intravitreal implant) — International operational (constant-currency) growth YoY (%)(%)			10.4%	-3.6%	4.4%	1.1%	3.5%	2.5%	9.5%	29.3%	15.4%	21.7%
Ozurdex (dexamethasone intravitreal implant) — Worldwide reported growth YoY (%)(%)			6.9%	-1.6%	0.6%	-6.0%	1.1%	-0.9%	4.5%	13.7%	12.3%	13.2%
Ozurdex (dexamethasone intravitreal implant) — Worldwide operational (constant-currency) growth YoY (%)(%)			4.3%	-4.0%	-0.4%	-2.4%	1.4%	1.1%	8.0%	14.6%	11.3%	12.8%
Lumigan/Ganfort (bimatoprost) — Worldwide net revenues ($M)($M)4			104	97	103	106	119	116	103	91	92	91
Lumigan/Ganfort (bimatoprost) — U.S. net revenues ($M)($M)1			47	42	52	48	58	58	42	29	31	28
Lumigan/Ganfort (bimatoprost) — U.S. reported growth YoY (%)(%)			-19.0%	-26.1%	19.9%	69.2%	83.9%		-15.8%	-55.0%	-44.1%	-53.0%
Lumigan/Ganfort (bimatoprost) — International net revenues ($M)($M)2			57	55	51	58	61	58	61	62	61	63
Lumigan/Ganfort (bimatoprost) — International reported growth YoY (%)(%)			-6.6%	-6.0%	-15.4%	-6.8%	0.9%	-7.0%	-11.2%	-7.6%	-9.9%	2.7%
Lumigan/Ganfort (bimatoprost) — International operational (constant-currency) growth YoY (%)(%)			-9.1%	-8.7%	-15.2%	-0.5%	2.2%	-2.7%	-8.1%	-6.4%	-11.9%	1.4%
Lumigan/Ganfort (bimatoprost) — Worldwide reported growth YoY (%)(%)			-12.6%	-15.9%	-0.8%	17.0%	29.4%	27.2%	-13.2%	-30.5%	-25.5%	-24.8%
Lumigan/Ganfort (bimatoprost) — Worldwide operational (constant-currency) growth YoY (%)(%)			-13.9%	-17.3%	-0.7%	21.4%	30.2%	30.2%	-11.4%	-29.9%	-26.6%	-25.5%
Alphagan/Combigan (brimonidine) — Worldwide net revenues ($M)($M)4			54	47	36	60	78	62	49	59	66	70
Alphagan/Combigan (brimonidine) — U.S. net revenues ($M)($M)1			18	9	0	26	41	26	13	15	31	30
Alphagan/Combigan (brimonidine) — U.S. reported growth YoY (%)(%)			-54.8%	-67.4%	-91.6%	68.5%	33.6%	-15.3%	-59.5%	-47.0%	-26.8%	-16.0%
Alphagan/Combigan (brimonidine) — International net revenues ($M)($M)2			36	38	36	34	37	36	36	44	35	40
Alphagan/Combigan (brimonidine) — International reported growth YoY (%)(%)			-4.5%	6.8%	-3.1%	-21.4%	6.8%	-10.0%	9.1%	1.9%	7.2%	10.1%
Alphagan/Combigan (brimonidine) — International operational (constant-currency) growth YoY (%)(%)			-5.4%	4.7%	-0.2%	-15.4%	10.2%	-4.5%	20.5%	6.9%	9.8%	17.3%
Alphagan/Combigan (brimonidine) — Worldwide reported growth YoY (%)(%)			-30.5%	-24.7%	-25.6%	1.9%	19.2%	-12.3%	-23.7%	-17.7%	-11.7%	-3.1%
Alphagan/Combigan (brimonidine) — Worldwide operational (constant-currency) growth YoY (%)(%)			-30.9%	-25.9%	-23.5%	6.3%	21.0%	-9.2%	-17.8%	-14.7%	-10.5%	0.4%
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — Worldwide net revenues ($M)($M)4							114	21	32	57	128	117
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — U.S. net revenues ($M)($M)1							102	8	18	44	117	104
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — U.S. reported growth YoY (%)(%)							-13.7%	-92.5%	-77.3%	-44.1%	13.5%	-20.7%
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — International net revenues ($M)($M)2							12	13	14	13	11	13
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — International reported growth YoY (%)(%)							14.9%	2.1%	-18.9%	-1.4%	44.7%	35.0%
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — International operational (constant-currency) growth YoY (%)(%)							19.7%	8.1%	-14.5%	4.1%	51.4%	42.1%
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — Worldwide reported growth YoY (%)(%)							-11.3%	-82.2%	-67.0%	-38.1%	15.6%	-17.0%
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — Worldwide operational (constant-currency) growth YoY (%)(%)							-10.9%	-81.5%	-66.2%	-37.3%	16.1%	-16.5%
Other Eye Care — Worldwide net revenues ($M)($M)4			294	248	250	217	329	228	257	257	617	207
Other Eye Care — U.S. net revenues ($M)($M)1			189	138	144	117	223	123	149	149	481	114
Other Eye Care — U.S. reported growth YoY (%)(%)			-14.9%	12.3%	-4.3%	-21.4%	20.9%	1.7%	18.9%	-4.8%	-2.5%	16.3%
Other Eye Care — International net revenues ($M)($M)2			105	110	106	100	106	105	108	108	136	93
Other Eye Care — International reported growth YoY (%)(%)			-1.5%	4.7%	-1.7%	-7.1%	15.4%	-2.0%	-10.1%	5.9%	9.7%	11.9%
Other Eye Care — International operational (constant-currency) growth YoY (%)(%)			-2.3%	3.5%	0.9%	-0.2%	20.3%	4.2%	-6.1%	9.3%	9.3%	12.0%
Other Eye Care — Worldwide reported growth YoY (%)(%)			-10.5%	8.8%	-3.2%	-15.4%	18.4%		4.8%		2.6%	14.2%
Other Eye Care — Worldwide operational (constant-currency) growth YoY (%)(%)			-10.8%	8.2%	-2.1%	-12.5%	20.6%	2.8%	6.7%	1.5%	2.4%	14.2%

Research and Development (R&D) Expense — GAAP ($M)($M)3	2,344	2,472	2,579	2,319	2,131	2,067	6,774	2,130	1,948	1,939	1,927	1,723
Adjusted R&D Expense — Non-GAAP ($M)($M)	2,314	2,268	18.3	2,256	2,115	14.2	20.2	2,055	1,917	14.8	17.2	15.7
GAAP R&D Expense % of Net Revenues (%)(%)	13.8%	16.5%	15.5%	14.7%	13.8%	15.5%	44.9%	14.7%	13.5%	15.8%
Adjusted R&D Expense % of Net Revenues — Non-GAAP (%)(%)	13.6%	15.1%	15.4%	14.3%	13.7%	15.4%	15.1%	14.2%	13.3%	14.7%
Acquired IPR&D and Milestones Expense — Upfront & Collaboration Charges ($M)($M)3	291	744	-3,149	2,680	823	248	-208	82	937	164	86	66
Development and Regulatory Milestones Recognized in R&D ($M)($M)	146	41	23	65	118	2	35	0	10	85	96	22
Acquired IPR&D and Milestones % of Net Revenues (%)(%)	1.7%	5.0%	7.6%	17.0%	5.3%	1.9%	10.4%	0.6%	6.5%	1.3%	2.0%	0.5%
Acquired IPR&D and Milestones Unfavorable Impact to Diluted EPS ($/sh)($)	0.17	0.41	0.71	1.50	0.42	0.13	0.88	0.04	0.52	0.08	0.15	0.04
Janssen Biotech Collaboration (Imbruvica) — International Profit Share in Net Revenues ($M)($M)1	195	224	202	199	211	209	223	210	238	228	220	230
Janssen U.S. Profit Share Recorded in AbbVie Cost of Products Sold ($M)($M)	157	153	219	235	253	247	291	282	284	283	320	316
Genentech Collaboration (Venclexta) — Profit Share & Royalties in Cost of Products Sold ($M)($M)	298	284	274	286	262	242	257	263	243	227	228	225

Adjusted Gross Margin Ratio — Non-GAAP (%)(%)1	84.7%	83.6%	83.6%	83.9%	84.4%	84.1%	83.8%	84.4%	85.2%	82.9%	83.9%	83.5%
GAAP Gross Margin Ratio (%)(%)	74.7%	71.9%	72.6%	66.4%	71.8%	70.0%	70.9%	70.9%	70.9%	66.7%	60.1%	53.4%
Adjusted Operating Margin Ratio — Non-GAAP (%)(%)1	48.3%	40.8%	38.3%	30.9%	44.3%	42.3%	34.7%	46.7%	42.6%	42.2%	43.8%	46.7%
GAAP Operating Margin Ratio (%)(%)	37.9%	26.6%	27.3%	12.1%	31.7%	28.0%		26.5%	27.6%	22.7%	22.3%	16.4%
Adjusted SG&A Expense % of Net Revenues — Non-GAAP (%)(%)1	21.0%	22.7%	22.3%	21.6%	21.0%	24.6%	23.6%	23.0%	22.9%	24.6%	24.7%	23.9%
GAAP SG&A Expense % of Net Revenues (%)(%)	21.4%	23.9%	23.4%	22.6%	21.1%	24.7%	25.5%	29.1%	23.3%	26.9%	22.3%	24.2%
Adjusted Effective Tax Rate — Non-GAAP (%)(%)2	14.7%	15.4%	18.3%	24.5%	16.2%	14.2%	20.2%	16.2%	18.8%	14.8%	17.2%	15.7%
GAAP Effective Tax Rate (%)(%)	15.5%	32.9%	32.0%	73.7%	39.4%	22.4%	99.0%	25.0%	36.0%	21.8%	32.1%	8.8%
Effective Tax Rate on Specified Items (%)(%)	13.7%	11.3%	7.0%	14.9%	8.6%	10.3%	45.4%	11.9%	8.7%	10.8%	13.4%	18.9%
Adjusted After-Tax Earnings — Non-GAAP ($M)($M)6	6,491	4,711	4,830	3,306	5,278	4,370	3,844	5,327	4,710	4,120	4,959	5,250
Reported After-Tax Earnings — GAAP ($M)($M)	3,613	695	1,816	186	938	1,286	-22	1,561	1,370	1,369	822	1,778
Adjusted Pre-Tax Earnings — Non-GAAP ($M)($M)	7,613	5,569	5,909	4,380	6,304	5,099	4,813	6,357	5,804	4,838	5,990	6,233
Reported Pre-Tax Earnings — GAAP ($M)($M)	4,278	1,039	2,668	714	1,554	1,661	-2,269	2,084	2,146	1,755	1,212	1,953
Adjusted Cost of Products Sold — Non-GAAP ($M)($M)	2,598	2,462	5,909	2,547	2,413	5,099	4,813	2,251	2,135	4,838	5,990	6,233
Adjusted SG&A Expense — Non-GAAP ($M)($M)	3,574	3,401	1,080	3,412	3,239	726	970	3,326	3,315	715	1,029	980
Adjusted Income Tax Expense — Non-GAAP ($M)($M)	1,119	856	1,080	1,072	1,023	726	970	1,027	1,091	715	1,029	980
Adjusted Diluted Earnings Per Share — Non-GAAP ($/sh)($)5	3.65	2.65	2.71	1.86	2.97	2.46	2.16	3	2.65	2.31	2.79	2.95
Reported Diluted Earnings Per Share — GAAP ($/sh)($)	2.03	0.39	1.02	0.10	0.52	0.72	-0.02	0.88	0.77	0.77	0.46	1
Total Specified Items — Pre-Tax ($M)($M)	3,335	4,530	3,241	3,666	4,750	3,438	7,082	4,273	3,658	3,083	4,778	4,280
Total Specified Items — Income Tax Impact ($M)($M)	457	514	227	546	410	354	3,216	507	318	332	641	808
Specified Item: Intangible Asset Amortization — Pre-Tax ($M)($M)2	1,689	1,748	1,784	1,871	1,864	1,858	1,896	1,888	1,947	1,891	1,889	2,039
Intangible Asset Amortization — After-Tax ($M)($M)	1,436	1,498	1,500	1,576	1,571	1,574	1,607	1,600	1,651	1,603	1,584	1,728
Intangible Asset Amortization — Diluted EPS Impact ($/sh)($)	0.81	0.85	0.85	0.89	0.89	0.89	0.90	0.89	0.93	0.90	0.89	0.98
Specified Item: Change in Fair Value of Contingent Consideration — Pre-Tax ($M)($M)2	1,518	2,387	1,406	776	2,795	1,518	279	1,356	1,476	660	1,696	8
Change in Fair Value of Contingent Consideration — After-Tax ($M)($M)	1,479	2,325	1,368	755	2,709	1,477	271	1,321	1,438	643	1,655	8
Change in Fair Value of Contingent Consideration — Diluted EPS Impact ($/sh)($)	0.83	1.31	0.77	0.43	1.53	0.83	0.15	0.75	0.81	0.36	0.93

Contingent Consideration Liability — Total Level 3 Fair Value ($M)($M)8	27,495	27,039	25,374	24,649	24,649	22,713	21,666	21,926	21,150	20,159	19,890	18,674
Level 3 Rollforward — Additions ($M)($M)	0	0	0	0	0	78	0	0	0	0
Level 3 Rollforward — Change in Fair Value Recognized in Earnings ($M)($M)	1,518	2,387	1,406	776	2,795	1,518	279	1,356	1,476	660	1,696	8
Level 3 Rollforward — Cash Settlements and Payments ($M)($M)1	1,062	722	681	776	859	549	539	580	485	391	480	485
Contingent Consideration Payments — Operating Cash Flow Portion ($M)($M)	1,062	722	681	776	859	549	539	580	485	391	463	391
Valuation Inputs — Discount Rate Minimum (%)(%)	4.2%	4.1%	4.8%	3.8%	4.0%	4.2%	4.6%	3.9%	4.8%	4.6%	4.3%	5.3%
Valuation Inputs — Discount Rate Maximum (%)(%)	5.5%	5.0%	3.7%	4.6%	4.8%	4.9%	5.2%	5.1%	5.9%	5.8%	5.9%	6.1%
Valuation Inputs — Discount Rate Weighted Average (%)(%)	4.5%	4.3%	4.0%	4.1%	4.3%	4.5%	4.8%	4.1%	5.0%	4.8%	4.5%	5.5%
Valuation Inputs — Payment Probability Maximum (%)(%)	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Valuation Inputs — Payment Probability Weighted Average (%)(%)	93.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.0%	99.0%	99.0%
Recorded Litigation Accrual Reserve ($M)($M)4	1,700	1,700	1,600	1,500	1,800	1,800	2,500	2,400			2,000
Net Litigation Reserve Charges / Adjustments ($M)($M)	-64	150	136	-319	-21	-729	167	314	39	-12	-238	-87
Pending Legal Claims — Prescription Opioid Lawsuits Total (cases)2	215	320	335	380	380	430	435	440	460	580	590	610
Pending Claims — Prescription Opioid State Lawsuits (cases)	20	20	25	25	25	30	35	35	45	165	175	160
Pending Claims — Prescription Opioid Municipal & Local Lawsuits (cases)	20	20	20	20	20	25	25	30
Pending Legal Claims — Biocell Textured Breast Implant ALCL State Lawsuits (cases)	475	75	75	75	75	75	75	75	75
Pending Legal Claims — Other Product Liability Lawsuits (cases)1	1,300	1,320	1,320	1,300	1,290	1,260	1,100	1,000	1,000
Pending Claims — International Product Liability Lawsuits (cases)	1,080	1,080	1,080	1,025	1,005	1,000	1,000	800	800

Inventories, Net ($M)($M)3	5,127	5,049	4,951	4,938	4,960	4,526	4,181	4,450	4,218	4,245	4,099	3,981
Finished Goods ($M)($M)	1,671	1,806	1,580	1,579	1,681	1,441	1,173	1,347	1,189	1,258	1,356	1,035
Work in Process ($M)($M)	2,316	2,137	2,287	2,277	2,113	1,974	1,951	2,071	1,930	1,890	1,643	1,690
Raw Materials ($M)($M)	1,140	1,106	1,084	1,082	1,166	1,111	1,057	1,032	1,099	1,097	1,100	1,256
Property, Plant and Equipment, Net ($M)($M)4	5,796	5,687	5,628	5,483	5,283	5,237	5,134	5,141	5,023	4,980	4,989	4,934
Property, Plant and Equipment, Gross ($M)($M)	13,955	13,731	13,530	13,229	12,934	12,571	12,267	12,279	11,903	11,725	11,635	11,374
Accumulated Depreciation ($M)($M)	8,159	8,044	7,902	7,746	7,651	7,334	7,133	7,138	6,880	6,745	6,646	6,440
Depreciation Expense ($M)($M)	194	188	203	192	186	181	206	191	184	183	187	196
Capital Expenditures ($M)($M)	322	265	329	381	269	235	291	249	241	193	205	219
Intangible Assets, Net ($M)($M)4	49,139	50,873	52,641	54,315	57,031	58,489	60,068	66,646	60,243	62,225	55,610	58,603
Goodwill ($M)($M)	35,519	35,570	35,640	35,626	35,638	35,285	34,956	35,295	33,386	33,426	32,293	32,091
Definite-Lived Intangible Assets, Net ($M)($M)4	44,738	45,601	47,360	49,034	51,745	53,198	54,866	56,951	58,663	60,645	55,307	58,318
Developed Product Rights, Net ($M)($M)2	44,077	44,785	46,390	47,874	50,396	51,657	53,175	54,998	56,446	58,160	52,687	55,356
Developed Product Rights, Gross ($M)($M)	81,968	81,165	81,239	81,126	82,150	81,638	81,428	81,721	81,497	82,219	75,142	76,526
Developed Product Rights, Accumulated Amortization ($M)($M)	37,891	36,380	34,849	33,252	31,754	29,981	28,253	26,723	25,051	24,059	22,455	21,170
License Agreements, Net ($M)($M)2	661	816	970	1,160	1,349	1,541	1,691	1,953	2,217	2,485	2,620	2,962
License Agreements, Gross ($M)($M)	8,359	8,359	8,353	8,353	8,352	8,352	8,315	8,316	8,315	8,316	8,191	8,261
License Agreements, Accumulated Amortization ($M)($M)	7,698	7,543	7,383	7,193	7,003	6,811	6,624	6,363	6,098	5,831	5,571	5,299
Definite-Lived Intangible Assets, Gross ($M)($M)	90,327	89,524	89,592	89,479	90,502	89,990	89,743	90,037	89,812	90,535	83,333	84,787
Definite-Lived Intangible Assets, Accumulated Amortization ($M)($M)	45,589	43,923	42,232	40,445	38,757	36,792	34,877	33,086	31,149	29,890	28,026	26,469
Indefinite-Lived IPR&D Intangible Assets ($M)($M)	4,401	5,272	5,281	5,281	5,286	5,291	5,202	9,695	1,580	1,580	303	285
Intangible Asset Amortization Expense ($M)($M)	1,700	1,700	1,800	1,900	1,900	1,900	1,900	1,900	1,900	1,900	1,800	2,000

Long-Term Debt and Finance Lease Obligations, Noncurrent ($M)($M)2	62,481	64,532	58,941	62,971	62,959	64,527	60,340	58,509	58,048	63,805	52,194	55,631
Current Portion of Long-Term Debt and Finance Leases ($M)($M)	8,341	8,326	6,056	1,982	1,966	3,769	6,804	12,570	12,586	10,193	7,191	5,113
Short-Term Borrowings ($M)($M)	0	0	2,499	3,790	5,556	1,593	0			3	0	2
Cash Dividends Declared ($M)($M)6	3,074	3,074	3,075	2,917	2,914	2,913	2,914	2,757	2,754	2,753	2,755	2,634
Dividends Declared per Common Share ($/sh)($)	1.73	1.73	1.73	1.64	1.64	1.64	1.64	1.55	1.55	1.55	1.55	1.48
Cash Paid for Purchases of Common Stock ($M)($M)	9	1,489	3	4	12	961	358	17	9	1,324	3	4
Common Stock Held in Treasury (M shares)	77.10	77.10	70.80	70.80	70.80	70.80	66.30	64.30	64.30	64.20	57.10	57.10
Treasury Stock Carrying Value ($M)($M)	10,618	10,611	9,146	9,143	9,147	9,137	8,201	7,848	7,838	7,829	6,533	6,525
Stock-Based Compensation Expense ($M)($M)	166	444	157	209	179	410	164	181	218	348	125	130
Stock-Based Compensation Tax Benefit ($M)($M)	29	75	31	35	34	70	32	33	34	60	25	26
Defined Benefit Pension Plans — Projected Benefit Obligation (PBO) [year-end] ($M)4
Net Periodic Pension Benefit Cost ($M)($M)	-14	-31	-14	-13	-6	-20	1	1	1	1	-1	-1
Pension Service Cost ($M)($M)	68	63	67	66	68	63	72	71	71	72	67	68
Pension Interest Cost ($M)($M)	128	122	121	122	124	117	112	113	113	113	108	108
Expected Return on Pension Plan Assets ($M)($M)	222	224	209	209	208	206	196	196	196	197	180	181
Other Post-Employment Benefit (OPEB) Plans — Benefit Obligation [year-end] ($M)3
Net Periodic OPEB Cost ($M)($M)	13	15	15	15	14	14	16	16	17	16	13	12
OPEB Service Cost ($M)($M)	10	11	10	10	10	10	11	11	10	11	10	9
OPEB Interest Cost ($M)($M)	10	11	11	11	11	11	10	10	11	10	9	9
Income Tax Expense ($M)($M)1	662	342	853	526	613	372	-2,246	520	773	383	388	172
Deferred Income Tax Expense (Benefit) ($M)($M)	-195	137	-385	193	-272	-28	-767	-277	-16	-389	-1,391	-863

PPI: Pharmaceutical Preparation Manufacturing (Index Dec 1981=100)	926.70	925.40	919.10	917.40	915.10	915.30	918.10	917.30	914.40	907.80	896.30	896.50
U.S. Retail Sales: Pharmacies and Drug Stores — Seasonally Adjusted ($M)($M)1	97,481	95,519	103,201	102,234	100,190	98,467	97,365	95,992	89,716	87,927	89,673	85,816
U.S. Retail Sales: Pharmacies and Drug Stores — Not Seasonally Adjusted ($M)($M)	97,059	93,047	106,419	102,171	99,818	95,892	100,312	95,792	89,173	86,987	91,914	85,089
Income Statement — Net revenues ($M)($M)14	16,990	15,002	16,618	15,776	15,423	13,343	15,102	14,460	14,462	12,310	14,301	13,927
Cost of products sold ($M)($M)	4,291	4,218	4,552	5,304	4,346	4,002	4,396	4,212	4,202	4,094	5,704	6,485
Total operating costs and expenses ($M)($M)	10,558	11,012	12,074	13,872	10,529	9,610	16,592	10,629	10,464	9,512	11,106	11,646
Selling, general and administrative expense ($M)($M)	3,632	3,578	3,895	3,569	3,253	3,293	3,855	4,205	3,377	3,315	3,193	3,372
Research and development expense ($M)($M)	2,344	2,472	2,579	2,319	2,131	2,067	6,774	2,130	1,948	1,939	1,927	1,723
Operating earnings ($M)($M)	6,432	3,990	4,544	1,904	4,894	3,733	-1,490	3,831	3,998	2,798	3,195	2,281
Interest expense ($M)($M)	746	717	714	739	740	700	702	720	726	660	564	555
Interest income ($M)($M)	67	72	59	72	62	73	92	129	220	207	186	157
Earnings before income tax ($M)($M)	4,278	1,039	2,668	714	1,554	1,661	-2,269	2,084	2,146	1,755	1,212	1,953
Income tax expense ($M)($M)	662	342	853	526	613	372	-2,246	520	773	383	388	172
Net earnings attributable to AbbVie Inc. ($M)($M)	3,601	685	1,806	176	928	1,276	-32	1,551	1,360	1,359	811	1,767
Earnings per share — Basic ($/sh)($)	2.04	0.39	1.02	0.10	0.52	0.72	-0.02	0.88	0.77	0.77	0.46	1
Earnings per share — Diluted ($/sh)($)	2.03	0.39	1.02	0.10	0.52	0.72	-0.02	0.88	0.77	0.77	0.46	1
Weighted-average basic shares outstanding (M)	1,769.00	1,770.00		1,769.00	1,768.00	1,768.00		1,769.00	1,768.00	1,769.00		1,767.00
Weighted-average diluted shares outstanding (M)	1,771.00	1,774.00		1,772.00	1,771.00	1,772.00		1,772.00	1,771.00	1,773.00		1,771.00
Balance Sheet — Total assets ($M)($M)12	135,115	136,463	133,960	133,898	137,182	136,165	135,161	143,422	141,937	148,874	134,711	136,221
Cash and equivalents ($M)($M)	6,569	9,391	5,229	5,629	6,467	5,175	5,524	7,257	13,130	18,067	12,814	13,287
Accounts receivable, net ($M)($M)	13,824	12,479	12,589	12,769	12,637	12,477	10,919	11,472	11,724	11,949	11,155	11,412
Inventories ($M)($M)	5,127	5,049	4,951	4,938	4,960	4,526	4,181	4,450	4,218	4,245	4,099	3,981
Total current assets ($M)($M)	33,669	33,529	29,062	28,539	29,261	27,675	25,582	27,785	33,816	38,871	33,002	33,224
Property and equipment, net ($M)($M)	5,796	5,687	5,628	5,483	5,283	5,237	5,134	5,141	5,023	4,980	4,989	4,934
Goodwill ($M)($M)	35,519	35,570	35,640	35,626	35,638	35,285	34,956	35,295	33,386	33,426	32,293	32,091
Intangible assets, net ($M)($M)	49,139	50,873	52,641	54,315	57,031	58,489	60,068	66,646	60,243	62,225	55,610	58,603
Accounts payable ($M)($M)	33,301	33,774	34,734	33,619	32,245	31,041	2,945	30,492	29,329	31,326	3,688	29,658
Total current liabilities ($M)($M)	41,642	42,100	43,289	39,391	39,767	36,403	38,749	43,062	41,915	41,522	37,841	34,773
Long-term debt and finance lease obligations ($M)($M)	62,481	64,532	58,941	62,971	62,959	64,527	60,340	58,509	58,048	63,805	52,194	55,631
Retained earnings ($M)($M)	-17,333	-17,872	-15,493	-14,234	-11,503	-9,527	-7,900	-4,964	-3,768	-2,384	-1,000	933
Total stockholders' equity (deficit) ($M)($M)	-5,888	-6,612	-3,228	-2,599	-138	1,462	3,364	6,071	6,821	8,047	10,397	12,129
Cash Flow Statement — Operating cash flow ($M)($M)3	3,436	3,829	5,218	7,024	5,153	1,635	7,048	5,447	2,271	4,040	4,753	7,574
Capital expenditures ($M)($M)	322	265	329	381	269	235	291	249	241	193	205	219
Cash dividends paid ($M)($M)	3,070	3,086	2,911	2,911	2,910	2,925	2,752	2,751	2,750	2,772	2,626	2,627
Purchases of common stock ($M)($M)	9	1,489	3	4	12	961	358	17	9	1,324	3	4

49 metrics have no data in the last 12 quarters — .

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics

Fiscal calendar: AbbVie Inc. operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026). AbbVie operates as a single global biopharmaceutical operating segment (Note 16), so commercial performance is tracked through Therapeutic Area portfolios and brand-level Worldwide / U.S. / International net revenues.
Core commercial & R&D KPIs (Groups 1–8) cover: (1) Consolidated Net Revenues ($17,264M in Q2 2026 / $61,160M in FY25 across U.S. $13,074M and International $4,190M in Q2 2026; +12.0% reported / +11.4% operational YoY), 12-country annual revenue disaggregation (U.S. $47,125M, Germany $1,622M, Japan $1,182M, Canada $1,167M, China $1,111M, France $963M, U.K. $763M, Spain $726M, Italy $650M, Brazil $544M, Australia $447M, Other $4,860M in FY25), and geographic long-lived assets ($11,833M in FY25); (2) Immunology Portfolio ($8,786M in Q2 2026 / $30,406M in FY25, +16.9% reported / +16.4% operational in Q2 2026: Skyrizi $5,505M, Rinvoq $2,525M, Humira $756M); (3) Neuroscience Portfolio ($3,228M in Q2 2026 / $10,767M in FY25, +20.3% reported / +19.8% operational: Vraylar $1,071M, Botox Therapeutic $1,042M, Ubrelvy $392M, Qulipta $350M, Vyalev $256M, Other Neuroscience $117M, plus Duodopa through Q4 2025); (4) Oncology Portfolio ($1,650M in Q2 2026 / $6,655M in FY25: Venclexta $771M, Imbruvica $532M, Elahere $211M, Epkinly $103M, Other Oncology $33M); (5) Aesthetics Portfolio ($1,269M in Q2 2026 / $4,854M in FY25: Botox Cosmetic $728M, Juvederm $245M, Other Aesthetics $296M), Other Key Products (Mavyret $319M, Creon $323M, Linzess/Constella $310M, All Other $1,379M in Q2 2026), Eye Care Portfolio ($2,068M in FY25: Ozurdex $497M, Lumigan/Ganfort $436M, Alphagan/Combigan $231M, Other Eye Care $904M; folded into All Other in Q1 2026), and legacy discontinued franchises; (6) Gross-to-Net (GTN) provisions ($44.9B rebates & chargebacks and $3.27B cash discounts in FY25), Accrued Sales Rebates ($17,032M at FY25), 14-year rollforwards of Medicaid/Medicare ($2,115M ending FY25), Managed Care ($13,544M ending FY25) & Wholesaler Chargebacks ($1,373M ending FY25), and U.S. wholesaler AR concentration (85% in FY25); (7) R&D & Acquired IPR&D ($2,356M GAAP / $2,315M Adjusted R&D and $142M upfront + $50M milestone IPR&D in Q2 2026; Janssen Imbruvica & Genentech Venclexta collaboration profit shares); and (8) GAAP vs. Non-GAAP margins (85.1% Adjusted Gross Margin, 48.0% Adjusted Operating Margin, $3.35 Adjusted Diluted EPS in Q2 2026; $10.00 Adjusted Diluted EPS in FY25) and Specified Items.
Groups 9–12 cover: (9) Level 3 Contingent Consideration Liabilities ($26,010M at Q2 2026; Skyrizi/Risankizumab additions, fair value changes, cash payments & discount rate / probability valuation inputs), Litigation Accrual Reserve ($1,395M at Q2 2026) and pending legal claims (Opioid, Biocell ALCL, Product Liability, Niaspan); (10) Inventories by stage ($5,112M net at Q2 2026: Finished Goods $1,427M, WIP $2,310M, Raw Materials $1,375M), PP&E by category ($6,456M net at Q2 2026; 272 facilities / 23M sq ft in FY25), Goodwill ($35,610M) & Intangibles ($54,752M net at Q2 2026 with 5-year estimated amortization schedule), and Operating Leases; (11) Debt & 5-year maturity schedule ($60,646M noncurrent long-term debt at Q2 2026), Capital Return ($3,081M dividends declared / $1.73 per share in Q2 2026; treasury stock & SBC), Defined Benefit Pension ($10,031M PBO / $11,226M plan assets / +$1,195M funded status at FY25) & OPEB plans, and Income Taxes (DTA/DTL breakdown & UTB rollforward $2,756M at FY25); and (12) Global Workforce (55,000 employees, 8% turnover, 34% internal hire rate, 6,500 new hires, 55% women globally, 58% women in STEM in FY25), CEO Pay Ratio (251:1 / $133,895 median employee in FY25), Form 11-K AbbVie Savings Plan ($14.80B net assets at FY25), Workplace Safety (0.11 TRIR / 0.04 LTIR in FY25), Product Quality (55 external / 7 FDA inspections in FY25), Form SD 3TG Suppliers (73 suppliers / 86% response rate in FY25), and Scope 1 & 2 GHG Emissions, Energy, Water & Waste.
No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures such as '>100.0%' are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Data updated 2026-10-26.

Every KPI on its own page

Full history, chart, sources and a citation for each metric

Consolidated Net Revenues, Country Disaggregation & Geographic Long-Lived Assets

Immunology Portfolio Net Revenues & Operational Growth (Skyrizi, Rinvoq, Humira)

Immunology Portfolio — Worldwide net revenues ($M) ($M)32 periods

Neuroscience Portfolio Net Revenues & Operational Growth (Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, Vyalev)

Neuroscience Portfolio — Worldwide net revenues ($M) ($M)25 periods

Oncology Portfolio Net Revenues & Operational Growth (Venclexta, Imbruvica, Elahere, Epkinly)

Oncology Portfolio — Worldwide net revenues ($M) ($M)32 periods

AbbVie Inc. (ABBV) operating KPIs

KPIs

Every KPI on its own page

Consolidated Net Revenues, Country Disaggregation & Geographic Long-Lived Assets

Immunology Portfolio Net Revenues & Operational Growth (Skyrizi, Rinvoq, Humira)

Neuroscience Portfolio Net Revenues & Operational Growth (Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, Vyalev)

Oncology Portfolio Net Revenues & Operational Growth (Venclexta, Imbruvica, Elahere, Epkinly)

Aesthetics, Other Key Products (Mavyret, Creon, Linzess), Eye Care & Legacy Product Portfolios

Gross-to-Net (GTN) Sales Rebates, Chargebacks, Discounts & Wholesaler Concentration

R&D Innovation, Acquired IPR&D Milestones & Strategic Oncology Collaborations (Janssen, Genentech)

GAAP vs. Non-GAAP Operational Margins, Specified Items & Earnings Reconciliation

Contingent Consideration Liabilities (Level 3 Rollforward & Valuation Inputs), Litigation & Restructuring

Inventories by Stage, PP&E & Facilities, Goodwill & Intangibles (5-Year Amortization) & Leases

Debt & 5-Year Maturity Schedule, Capital Return, Defined Benefit Pension/OPEB & Income Taxes

Global Workforce, Diversity, 401(k) Savings Plan, Safety, Quality & Environmental Sustainability (ESG)

Industry & Macro Healthcare Benchmarks (FRED) & Core Financial Statements (DB)